NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Descending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00002-2980-60 | 00002-2980 | Selpercatinib | RETEVMO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
00781-2322-46 | 00781-2322 | Aprepitant | Aprepitant | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec. 27, 2016 | In Use | |
00781-2322-68 | 00781-2322 | Aprepitant | Aprepitant | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec. 27, 2016 | In Use | |
00469-0725-60 | 00469-0725 | enzalutamide | Xtandi | 80.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 4, 2020 | In Use | |
00310-1350-30 | 00310-1350 | Osimertinib | Tagrisso | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 13, 2015 | In Use | |
00310-1350-95 | 00310-1350 | Osimertinib | Tagrisso | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | March 15, 2019 | In Use | |
13668-0592-84 | 13668-0592 | APREPITANT | APREPITANT | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
13668-0592-86 | 13668-0592 | APREPITANT | APREPITANT | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
54868-5231-01 | 54868-5231 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | June 29, 2005 | In Use | |
54868-5231-02 | 54868-5231 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | June 29, 2005 | In Use | |
54868-5231-03 | 54868-5231 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | June 29, 2005 | In Use | |
00006-0461-01 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-02 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-06 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | April 30, 2020 | In Use |
00006-0461-12 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-30 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | July 14, 2010 | In Use |
72579-0011-01 | 72579-0011 | Zanubrutinib | BRUKINSA | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Nov. 14, 2019 | Sept. 30, 2021 | In Use |
72579-0011-02 | 72579-0011 | Zanubrutinib | BRUKINSA | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Nov. 14, 2019 | In Use | |
64842-1020-01 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct. 7, 2015 | In Use | |
64842-1020-02 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov. 11, 2015 | In Use | |
64842-1020-03 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct. 21, 2015 | In Use | |
00093-7236-19 | 00093-7236 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 16, 2009 | July 31, 2016 | No Longer Used |
00093-7236-33 | 00093-7236 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | Jan. 31, 2014 | No Longer Used |
00093-7236-56 | 00093-7236 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2007 | July 31, 2016 | No Longer Used |
00093-7236-93 | 00093-7236 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 14, 2010 | Jan. 31, 2014 | No Longer Used |
Found 9,752 results in 3 milliseconds — Export these results